Vertex Pharmaceuticals (VRTX) Capital Leases (2011 - 2025)
Vertex Pharmaceuticals (VRTX) posted quarterly Capital Leases of $111.4 million for Q1 2025, down 69.18% year-over-year from $361.5 million in Q1 2024, and down 1.24% quarter-over-quarter from $112.8 million in Q4 2024.
Vertex Pharmaceuticals (VRTX) Capital Leases (2011 - 2025) Analysis & Trends
Vertex Pharmaceuticals' Capital Leases history runs 15 years deep, the most recent figure standing at $111.4 million for Q1 2025.
- In Q1 2025, Capital Leases fell 69.18% year-over-year to $111.4 million; the TTM figure through Mar 2025 stood at $111.4 million (down 69.18% YoY), while the FY2024 annual figure was $112.8 million, down 70.01% from the prior year.
- Capital Leases for Q1 2025 stood at $111.4 million, down from $112.8 million in the prior quarter.
- The five-year high for Capital Leases was $530.3 million in Q1 2021, with the low at $111.4 million in Q1 2025.
- The 5-year median for Capital Leases is $417.6 million (2023), against an average of $386.1 million.
- The sharpest annual moves came in 2021 and 2024: Capital Leases climbed 0.55% in 2021, then plunged 70.79% in 2024.
- Vertex Pharmaceuticals' Capital Leases stood at $509.8 million in 2021, then declined by 15.5% to $430.8 million in 2022, then retreated by 12.7% to $376.1 million in 2023, then slumped by 70.01% to $112.8 million in 2024, then decreased by 1.24% to $111.4 million in 2025.
- Business Quant data shows VRTX's Capital Leases at $111.4 million in Q1 2025, $112.8 million in Q4 2024, and $114.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 111.40 Mn |
| Dec 31, 2024 | 112.80 Mn |
| Sep 30, 2024 | 114.00 Mn |
| Jun 30, 2024 | 346.60 Mn |
| Mar 31, 2024 | 361.50 Mn |
| Dec 31, 2023 | 376.10 Mn |
| Sep 30, 2023 | 390.30 Mn |
| Jun 30, 2023 | 404.10 Mn |
| Mar 31, 2023 | 417.60 Mn |
| Dec 31, 2022 | 430.80 Mn |
| Sep 30, 2022 | 442.30 Mn |
| Jun 30, 2022 | 482.30 Mn |
| Mar 31, 2022 | 495.50 Mn |
| Dec 31, 2021 | 509.80 Mn |
| Sep 30, 2021 | 513.26 Mn |
| Jun 30, 2021 | 524.93 Mn |
| Mar 31, 2021 | 530.33 Mn |
| Dec 31, 2020 | 539.00 Mn |
| Sep 30, 2020 | 546.51 Mn |
| Jun 30, 2020 | 522.07 Mn |